지씨셀

144510KOSDAQ

48.2 / 100

Reference Date: 2026-09-08

Financial Score14.5 / 40

News Sentiment16.7 / 25

Momentum7.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Slightly up 3.2% over the past month, and news sentiment is negative.

Company InformationBased on 2025 Annual Report

Business Overview

GC Cell is a company primarily engaged in the development and commercialization of cell therapies, specimen testing, cord blood banking, bio-logging, and CDMO services. The company is focusing on the development of NK and T cell therapies and is advancing research on next-generation CAR-NK and CAR-T treatments.

Number of Employees

806people

Average Salary

48.9M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

1.25Industry Average 1.202.5Point

Higher than industry avg (caution)

ROE

-83.81Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

18.04Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20250.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼6.1% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼279.8% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -33.0% (declining, 3yr)

Detailed News Sentiment

3 totalPositive 1Neutral 0Negative 2Average Sentiment Score 66.7

Negative
국공립병원 검체검사 입찰 짬짜미 의혹... 공정위 제재 착수
공정거래위원회가 국공립병원 검체 검사 입찰에서 짬짜미 의혹에 따라 제재를 시작함으로써 지씨셀의 관련 사업 부문에 부정적 영향이 예상됨.
Negative
공정위, '검체검사 12년 담합 의혹' 7개 업체 제재 착수
공정거래위원회의 제재로 인해 지씨셀 관련 검체검사 사업에 부정적 영향 예상.
Positive
지씨셀, 손주희 BD 실장 영입…글로벌 파트너십 강화
지씨셀의 손주희 BD 실장 영입으로 글로벌 파트너십 강화 및 사업개발 역량 향상 기대.

Detailed Momentum

52-week position1.0Point

Near 52w low (16%, downtrend)

Current 15,100Won52-week high 27,50052-week low 12,710

1-month return4.0Point

1m +3.21% (slight rise)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral반기보고서 (2026.06)2026-08-14